Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490869 | 0.81 | LMNA (0.48) | LMNACYP3A4CYP2C8CYP2C9CYP2B6 | |
| SCHEMBL12802565 | 0.81 | CYP1A2 (0.55) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL12802949 | 0.81 | CYP1A2 (0.55) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL12802442 | 0.81 | CYP1A2 (0.55) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL12802673 | 0.81 | CYP1A2 (0.55) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL12803112 | 0.81 | CYP3A4 (0.45) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL490646 | 0.81 | CYP3A4 (0.58) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL11232181 | 0.78 | ALDH1A1 (0.66) | LMNACYP3A4CYP1A2CA2ALDH1A1 | |
| SCHEMBL12802309 | 0.77 | HTR1A (0.58) | CYP3A4CYP2C8CYP2C9CYP2B6CYP2C19 | |
| SCHEMBL490645 | 0.77 | LMNA (0.50) | LMNACYP3A4CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422233-B2 | Vanilloid fatty hydroxamates as therapeutic anti-inflammatory pharmaceuticals | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-08-23 | — | — | US | disclosed |
| US-20120252891-A1 | Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252891-A1 | Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals | FAAH, FAAH2, TRPV1 | LMNA 3730/4885CYP3A4 1025/4885CYP2C8 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.